Apixaban
Reading File
Finding Sources
Searching the Web
apixaban pharmacology mechanism clinical uses 2025
Searching PubMed
apixaban
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
I now have excellent content from multiple authoritative textbooks. Let me compile the comprehensive answer:
Apixaban (Eliquis)
Drug Class
Oral, direct Factor Xa inhibitor (direct oral anticoagulant / DOAC)
Mechanism of Action
Apixaban inhibits both free and clot-bound Factor Xa directly and reversibly. By blocking Factor Xa, it reduces thrombin generation, which in turn suppresses both platelet aggregation and fibrin clot formation. It does not require antithrombin as a cofactor (unlike heparin).
Goodman & Gilman's Pharmacological Basis of Therapeutics, 14th Ed.
Pharmacokinetics (ADME)
| Parameter | Value |
|---|---|
| Oral bioavailability | ~50% |
| Time to peak (Tmax) | 1–3 hours |
| Protein binding | 87% |
| Renal elimination (unchanged) | ~27% |
| Metabolism | Hepatic CYP3A4 |
| Metabolite excretion | Bile, intestines, urine |
| Half-life | ~12 hours |
- Food does not affect absorption — can be taken with or without meals
- Tablet may be crushed and delivered via nasogastric tube
- Primarily metabolized by CYP3A4 and is a substrate of P-glycoprotein (P-gp)
Approved Indications
- Stroke and systemic embolism prevention in non-valvular atrial fibrillation (AF)
- Prophylaxis of DVT following hip or knee replacement surgery
- Treatment of DVT and PE (acute phase)
- Reduction of recurrent DVT/PE (extended secondary prevention)
- VTE treatment and recurrence reduction in pediatric patients (added 2025 FDA labeling)
Dosing
| Indication | Dose |
|---|---|
| Non-valvular AF (stroke prevention) | 5 mg PO twice daily |
| Acute DVT/PE treatment | 10 mg twice daily × 7 days, then 5 mg twice daily |
| Secondary prevention (post 6 months) | 2.5 mg twice daily |
| Post hip/knee replacement prophylaxis | 2.5 mg twice daily |
Dose Reduction Criteria (2 of 3 required → reduce to 2.5 mg BID):
- Age ≥ 80 years
- Body weight ≤ 60 kg
- Serum creatinine ≥ 1.5 mg/dL
Drug Interactions
| Interacting Drug/Class | Effect | Action |
|---|---|---|
| Combined P-gp + strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir) | ↑ Apixaban levels | Reduce dose by 50% (or avoid if on 2.5 mg BID) |
| Combined P-gp + strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's Wort) | ↓ Apixaban levels | Avoid combination |
| Anticoagulants / antiplatelet agents | ↑ Bleeding risk | Use with caution |
| NSAIDs | ↑ Bleeding risk | Use with caution |
Adverse Effects
- Bleeding is the major adverse effect (surgical sites, GI tract, intracranial)
- Compared to warfarin in AF: lower intracranial bleeding risk, broadly similar or lower major bleeding rates
- Compared to dabigatran: lower GI bleeding risk in elderly
Laboratory Effects
- Prolongs PT and aPTT in a concentration-dependent manner, but both tests are relatively insensitive at therapeutic concentrations and should not be used for monitoring
- No routine coagulation monitoring required (unlike warfarin)
Contraindications / Special Warnings
| Situation | Guidance |
|---|---|
| Mechanical prosthetic heart valves | Contraindicated |
| Triple-positive antiphospholipid syndrome | Not recommended |
| Hemodynamically unstable PE or requiring thrombolysis | Use not recommended |
| Pregnancy | Avoid (risk of fetal hemorrhage) |
| Severe hepatic impairment | Avoid |
| Spinal/epidural anesthesia | Risk of spinal hematoma — time carefully |
⚠️ Black Box Warning: Premature discontinuation increases the risk of thrombotic events. Do not stop without establishing adequate alternative anticoagulation.
Reversal Agent
Andexanet alfa (Andexxa / Factor Xa [recombinant]) — a recombinant modified human Factor Xa that binds to apixaban (and rivaroxaban) and neutralizes its anticoagulant effect. Indicated for life-threatening or uncontrolled bleeding. Associated with serious thromboembolic events post-reversal; resume anticoagulation as soon as medically appropriate.
- Not approved for edoxaban reversal.
Lippincott Illustrated Reviews: Pharmacology
Comparison with Other DOACs
| Feature | Apixaban | Rivaroxaban | Dabigatran | Edoxaban |
|---|---|---|---|---|
| Target | Factor Xa | Factor Xa | Thrombin (IIa) | Factor Xa |
| Dosing (AF) | 5 mg BID | 20 mg OD | 150 mg BID | 60 mg OD |
| Bioavailability | ~50% | ~80% | ~6% | ~62% |
| Renal clearance | ~27% | ~33% | ~80% | ~35–50% |
| Reversal agent | Andexanet alfa | Andexanet alfa | Idarucizumab | None approved |
Key Clinical Trials
- ARISTOTLE (AF stroke prevention): Apixaban superior to warfarin in reducing stroke/systemic embolism, with less major bleeding and lower mortality
- AMPLIFY (acute VTE): Apixaban non-inferior to enoxaparin/warfarin with significantly less bleeding
- AMPLIFY-EXT (extended VTE prevention): Both 5 mg and 2.5 mg BID doses superior to placebo for preventing recurrent VTE; 2.5 mg BID had similar efficacy with less bleeding
- ADVANCE-1, -2, -3: Established 2.5 mg BID for orthopedic prophylaxis
Recent Evidence (2025)
- API-CAT trial (ACC 2025): Lower-dose apixaban (2.5 mg BID) shown effective and safer vs. full dose for preventing VTE recurrence in patients with cancer — potentially expanding its role in cancer-associated thrombosis. [PMID 40464082] — a 2025 meta-analysis also confirms apixaban has significantly lower intracranial hemorrhage risk vs. aspirin.
Sources: Goodman & Gilman's Pharmacological Basis of Therapeutics, 14th Ed. | Lippincott Illustrated Reviews: Pharmacology | Fuster & Hurst's The Heart, 15th Ed. | Harrison's Principles of Internal Medicine, 22nd Ed. | FDA Prescribing Information (updated April 2025)
This is a shared conversation. Sign in to Orris to start your own chat.